Viridian Therapeutics: Promising Future with Strategic Trials and Financial Stability
I'm PortAI, I can summarize articles.
Viridian Therapeutics is viewed positively by analyst Serge Belanger, who has issued a Buy rating due to the company's promising future. The completion of enrollment for Phase 3 REVEAL trials for drug VRDN-003 is a significant milestone, with results expected in 2026. The company has also filed a Biologics License Application for its drug veli, with FDA acceptance anticipated soon. Financially, Viridian has secured up to $889 million, enhancing its stability for future developments. Wedbush also maintains a Buy rating with a $42 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments